This bill permanently requires New Jersey health insurance carriers to pay the same reimbursement rate for telemedicine and telehealth services as they do for in-person visits, provided the service is otherwise covered. It ensures patients face no higher deductibles, copays, or coinsurance for telehealth compared to in-person care. The law prohibits insurers from restricting where telehealth services can occur, limiting which technology platforms providers can use, or denying coverage for routine remote monitoring. It directly affects health insurance companies, healthcare providers offering telehealth, and patients receiving covered telehealth services. The policy change applies to all health benefits plans in New Jersey without time limits.
This bill requires social media platforms with significant user activity in New Jersey to display prominent warning labels about mental health risks during account sign-up and when users access certain features. It specifically targets platforms that allow social interaction (like profile creation and content sharing) and directly affects minors under 18, as defined by the bill. The warnings must highlight risks identified by the U.S. Surgeon General, including links between heavy social media use and increased depression, anxiety, and sleep disruption in youth. Platforms must comply with these labeling requirements to inform users and families about potential harms. The bill does not impose additional restrictions beyond the warning labels.
This bill would require New Jersey Medicaid to cover ovulation-enhancing drugs and related medical services without restrictions for beneficiaries experiencing infertility. It directly affects low-income New Jersey residents enrolled in Medicaid who seek infertility treatment. The key provision amends Medicaid law to explicitly include these services as a standard benefit, removing prior authorization requirements. This change would expand current coverage to ensure these treatments are accessible as routine care for eligible individuals.
This bill (A 964) creates a 15-member "Nursing Home Emergency Preparedness Study Commission" to analyze how New Jersey nursing homes respond to public health emergencies. The commission will examine nursing home environments, emergency policies, staffing levels, and funding needs during crises, and make recommendations to improve resident safety. It includes state health and human services officials, nursing home industry representatives (appointed by legislative leaders), and family members of residents (appointed by the Governor). The commission must submit a report to the Governor and Legislature within 12 months of its first meeting and then expire. This is a procedural study bill with no immediate policy changes, focusing on future recommendations.
This bill creates a statewide stockpile of essential medicines, vaccines, and medical supplies to be managed by New Jersey's Department of Health and State Office of Emergency Management. The stockpile, funded by state appropriations, will be used during emergencies like natural disasters, disease outbreaks, or public health crises. Key provisions require the state to establish distribution guidelines prioritizing healthcare providers in rural and medically underserved areas, with supplies managed through contracts that may include vendor-managed "virtually sequestered" inventories to prevent expiration. The bill mandates demand planning to determine stockpile contents and quantities based on emergency scenarios.
This bill expands New Jersey's existing requirement for health insurance plans to cover prostate cancer screenings without any out-of-pocket costs. It specifically requires coverage for annual screenings - including digital rectal exams and PSA tests - for men aged 50 and older (asymptomatic) and men aged 40 and older with a family history of prostate cancer or other risk factors. The law applies to most health insurance plans, including high-deductible plans where permitted by federal law, and mandates coverage "to the same extent as for any other medical condition." It does not alter existing coverage for other preventive services but ensures no cost-sharing (like deductibles or copays) applies to these specific screenings.
This bill exempts drug manufacturers and distributors from New Jersey's pharmacy licensing requirements when distributing dialysate drugs and devices used for home dialysis treatment of end-stage renal disease patients. It directly affects dialysis manufacturers, distributors, and patients receiving home dialysis, allowing them to bypass standard pharmacy licensing rules under six specific conditions. Key provisions include requiring FDA approval, direct delivery only upon physician orders, original sealed packaging, and mandatory weekly quality checks by a consultant pharmacist. The law ensures these products are handled safely while streamlining access for patients needing home dialysis.
This New Jersey bill creates a new crime called fertility fraud, which specifically targets licensed health care practitioners who knowingly use a patient's reproductive material without their written consent. Under the law, a practitioner commits this offense if they use their own sperm or eggs or the material of another person to cause a pregnancy without the patient's informed agreement. If convicted of this third-degree crime, the individual faces up to five years in prison, a fine of $15,000, and the mandatory permanent revocation of their medical license. Additionally, the legislation extends the statute of limitations for prosecuting this specific offense to 20 years from the date of the treatment or 10 years from when the victim discovers the fraud, whichever is later.
This bill requires state agencies to assess substance and alcohol use disorder treatment providers for conflicts of interest before approving state funding, licensure, or certification. Providers must submit detailed financial information, board member details, and lists of stakeholders with financial ties. If a conflict is identified that could affect care quality, the provider has 90 days to resolve it or risk losing funding/approval. After resolution, providers must undergo two additional conflict assessments within the next year. The law applies to all licensed or certifying state entities and defines conflicts as situations where outside financial interests might influence treatment decisions.
This bill prohibits the $0.50 surcharge on rideshare trips that are designated for paratransit service, which includes transportation for people with disabilities and Medicaid non-emergency medical transport. It directly affects users of apps like Uber and Lyft who rely on these services for accessibility needs, ensuring they are not charged the extra fee required for regular prearranged rides. The legislation also clarifies that transportation network companies are not personally liable for these specific paratransit trips. By amending existing state laws, the bill removes the financial barrier for eligible riders while maintaining the surcharge for standard rides.
